PubMed Health⌕ Search

PubMed · 16811272

Additional techniques for producing multiple-schedule control in children.

Abstract

The subjects in these experiments were 132 children, varying in age from 4 to 7 years. These experiments were designed to assess the efficacy of various multiple scheduling procedures in producing reliable stimulus control. The schedules studied were multiple fixed-ratio-extinction (mult FR EXT); multiple differential-reinforcement-of-other-behavior-fixed-ratio (mult DRO FR); multiple differential-reinforcement-for-low-rate-fixed-ratio (mult DRL FR); and multiple fixed-interval-fixed-ratio (mult FI FR). In addition other techniques were investigated, such as presenting FR's in blocks; increasing the size of the FR's; attaching a DRL to the FI members; temporarily shifting to new schedules; and adding an external clock to the FI's. These experiments yielded the following results.1.) Strong stimulus control was produced by mult FR EXT, mult DRO FR, and mult DRL FR schedules. Control for mult FR EXT was mediated principally by the individual stimuli, though on occasion it was dependent in part on the change of stimuli. The mult DRO FR was found to be highly useful for those children who had very high initial rates or who were generally uncooperative and unmanageable.2.) Contrary to a previous finding, some subjects were brought under stimulus control by means of mult FI FR schedules without the aid of additional procedures. Most, however, were not. Additional techniques found to augment the development of mult FI FR control included: (1) presenting FR's in blocks; (2) increasing the size of the FR's; (3) attaching a DRL to the FI component for a time and later removing it; and (4) shifting to a mult DRL FR, developing control, and then returning to the original mult FI FR.3.) Addition of an external clock to the FI components of the mult FI FR had several effects. Strongest control, including well-developed acceleratory patterns during the FI's, was developed in those subjects who had first been shifted from a regular mult FI FR to a mult FR EXT, brought under control, and then returned to the mult FI FR with the clock added. The added clock also produced strong control if it was present when the subject was first begun on a mult FI FR schedule. In some cases, the addition of the clock produced control in subjects who had not been controlled previously by the regular mult FI FR, but these were always subjects who had high rates. The addition of the clock first lowered the rate, then produced control.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E R Long. 1962. Additional techniques for producing multiple-schedule control in children.. https://doi.org/10.1901/jeab.1962.5-443

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗